Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jun 06, 2021 1:46pm
101 Views
Post# 33337583

RE:RE:RE:RE:RE:Exelon ...

RE:RE:RE:RE:RE:Exelon ...
Stockoman1 wrote: Is Chi-Chi confused ?   Funny he says  Sanofi  sold Exelon, but  I could swear it was Novartis that sold it to Knight !  


Correct Stockoman ... it is Novartis.
Chi-Chi may be rather confused about a few things - including that fact that he hasn't invested a dime in any company ... let alone in the pharma industry.
He'd like to - but he's not confident enough to lay down a dime.
That's what I understand about that guy.

Also - he betrayed this investor community by pretending to be a lady from Mainland China - a disgraceful play with no real purpose but to mislead.

--------

We do need better meds for Alzheimers ... we're just not going to see a step-function improvement with any new drug (IMO).  We may see encouraging news (50/50 chance right now) on Monday but that's just the beginning of a long journey to South America for such a drug - if accepted.  South America and Canada together represent about 7% of the global market and Big Pharma isn't focused on these regions.  That's the beauty of what GUD is creating in the Americas ... an opportunity to elevate the gegraphic worth as a partner of choice.

Here's an interesting article about why this coming drug from Biogen may still have its own issues, should the FDA give it the thumbs-up ... 

"I think the company is wrong, and I agree with the analyses by the Institute for Clinical and Economic Review; the data to make this case are murky and, even if they were clear, the drug’s benefits are ambiguous at best and not worth this cost. Putting it on the market will stress Medicare’s resources."

https://www.statnews.com/2021/05/30/if-the-fda-approves-biogens-alzheimers-treatment-i-wont-prescribe-it/

So ya ... I wish with all my heart that Biogen can help the many families out there who have to deal with this awful desease (my family included) but I'm not holding my breath.

I have already subscribed to the benefits of H2S and other gaseous mediators.  I feel the future of improved cell communication and cell function will allow for less active ingredient (for Alzheimer's/Parikinson's) but with a magnified effect.  I'm also guessing GUD will also be subscribing to that approach as they have chosen to partner with leading H2S researchers and a likely future Nobel Prize winner.

https://www.drugtargetreview.com/news/80680/hydrogen-sulphide-could-help-to-treat-alzheimers-disease/

-------------

Cheers ... here's to the future !

<< Previous
Bullboard Posts
Next >>